NO992374L - Behandling av neurodegenerative tilstander med nimesulid - Google Patents

Behandling av neurodegenerative tilstander med nimesulid

Info

Publication number
NO992374L
NO992374L NO992374A NO992374A NO992374L NO 992374 L NO992374 L NO 992374L NO 992374 A NO992374 A NO 992374A NO 992374 A NO992374 A NO 992374A NO 992374 L NO992374 L NO 992374L
Authority
NO
Norway
Prior art keywords
nimesulide
treatment
neurodegenerative conditions
neurodegeneration
discovery
Prior art date
Application number
NO992374A
Other languages
English (en)
Norwegian (no)
Other versions
NO992374D0 (no
Inventor
Giulio Maria Pasinetti
Paul S Aisen
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of NO992374D0 publication Critical patent/NO992374D0/no
Publication of NO992374L publication Critical patent/NO992374L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083Miscellaneous (1.14.99)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • A01K2267/0312Animal model for Alzheimer's disease
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • A01K2267/0318Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00Cells related to new breeds of animals
    • C12N2517/02Cells from transgenic animals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO992374A 1996-11-21 1999-05-18 Behandling av neurodegenerative tilstander med nimesulid NO992374L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3333296P 1996-11-21 1996-11-21
US08/831,402 US5985930A (en) 1996-11-21 1997-04-01 Treatment of neurodegenerative conditions with nimesulide
PCT/US1997/021484 WO1998022104A2 (en) 1996-11-21 1997-11-19 Treatment of neurodegenerative conditions with nimesulide

Publications (2)

Publication Number Publication Date
NO992374D0 NO992374D0 (no) 1999-05-18
NO992374L true NO992374L (no) 1999-07-21

Family

ID=26709565

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992374A NO992374L (no) 1996-11-21 1999-05-18 Behandling av neurodegenerative tilstander med nimesulid

Country Status (18)

Country Link
US (3) US5985930A (da)
EP (1) EP0956009B9 (da)
JP (1) JP2001505206A (da)
KR (1) KR20000069061A (da)
AT (1) ATE212546T1 (da)
AU (1) AU725141B2 (da)
BR (1) BR9714303A (da)
CA (1) CA2272249A1 (da)
DE (1) DE69710224T2 (da)
DK (1) DK0956009T3 (da)
ES (1) ES2172822T3 (da)
IL (1) IL129949A (da)
NO (1) NO992374L (da)
NZ (1) NZ335726A (da)
PT (1) PT956009E (da)
SK (1) SK284334B6 (da)
TR (1) TR199901120T2 (da)
WO (1) WO1998022104A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6441152B1 (en) * 1998-12-08 2002-08-27 Boston Probes, Inc. Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices
MXPA01008606A (es) * 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
CA2386190C (en) 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
US20040063752A1 (en) * 2002-05-31 2004-04-01 Pharmacia Corporation Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX-2) inhibitor(s)
EP1549303A4 (en) * 2002-06-13 2007-08-08 Sinai School Medicine INHIBITION OF PROGRESSIVE COGNITIVE IMPAIRMENT
US20060041022A1 (en) * 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
AU2003218345A1 (en) * 2002-11-06 2004-06-03 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
UA82093C2 (uk) 2003-03-31 2008-03-11 Уайт Фтор- та трифторалкіловмісні гетероциклічні сульфонамідні інгібітори утворення бета-амілоїду та їх похідні
US20090155903A1 (en) * 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
JP2012520883A (ja) * 2009-03-16 2012-09-10 アイピントゥル,エルエルシー アルツハイマー病及び骨粗鬆症の治療並びに老化の軽減
US8324450B2 (en) 2009-06-02 2012-12-04 Academia Sinica Non-human animal model for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP3524676A1 (en) 2011-12-16 2019-08-14 The Board of Trustees of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
EP2968586B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
CN105829538A (zh) 2013-08-14 2016-08-03 小利兰·斯坦福大学托管委员会 用于控制疼痛的组合物和方法
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
EP3122761B1 (en) 2014-03-28 2019-03-06 The Board of Trustees of The Leland Stanford Junior University Engineered light-activated anion channel proteins and methods of use thereof
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ, インコーポレイテッド メッセンジャーrnaの精製方法
US11168369B2 (en) 2014-11-25 2021-11-09 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
WO2017040538A1 (en) 2015-08-31 2017-03-09 The Board Of Trustees Of The Leland Stanford Junior University Compressed sensing high resolution functional magnetic resonance imaging
WO2017100058A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for functional brain circuit analysis
KR102855002B1 (ko) 2016-02-01 2025-09-04 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 기능성 영상 데이터 분석 방법 및 시스템
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
CN118421617A (zh) 2018-08-24 2024-08-02 川斯勒佰尔公司 用于纯化信使rna的方法
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Type II stable opsins and methods of using them
WO2021055609A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
WO2025189030A1 (en) 2024-03-07 2025-09-12 Stellaromics, Inc. Methods and systems for volumetric imaging

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3403096A (en) * 1963-10-02 1968-09-24 Ceskoslovenska Akademie Ved Method and device for separation of a suspension
US4966692A (en) * 1989-05-05 1990-10-30 Flint & Walling, Inc. Filtration system having flow control means and tank adapter with selective venting
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
ES2301161T3 (es) * 1994-07-27 2008-06-16 Vanderbilt University Compuestos de dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CA2164559A1 (en) * 1994-12-09 1996-06-10 Chun-Sing Li 5-methanesulfonamido-6-(2-pyridylthio)-1-indanones as inhibitors of cyclooxygenase-2
EP0799218B1 (en) * 1994-12-21 2003-02-19 Merck Frosst Canada & Co. Diaryl-2-(5h)-furanones as cox-2 inhibitors
CA2211320C (en) * 1995-01-31 2007-03-20 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
ATE223390T1 (de) * 1995-02-13 2002-09-15 Searle & Co Substituierte isoxazole zur behandlung von entzündung
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
ITMI962356A1 (it) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide

Also Published As

Publication number Publication date
CA2272249A1 (en) 1998-05-28
AU5361298A (en) 1998-06-10
US20060059576A1 (en) 2006-03-16
KR20000069061A (ko) 2000-11-25
IL129949A (en) 2003-05-29
WO1998022104A3 (en) 1998-10-08
AU725141B2 (en) 2000-10-05
SK284334B6 (sk) 2005-02-04
BR9714303A (pt) 2000-04-25
TR199901120T2 (xx) 1999-07-21
JP2001505206A (ja) 2001-04-17
PT956009E (pt) 2002-07-31
EP0956009B9 (en) 2002-12-11
SK67199A3 (en) 2001-01-18
US5985930A (en) 1999-11-16
WO1998022104A2 (en) 1998-05-28
US20020162130A1 (en) 2002-10-31
DK0956009T3 (da) 2002-05-21
US7226948B2 (en) 2007-06-05
ATE212546T1 (de) 2002-02-15
DE69710224T2 (de) 2002-10-02
DE69710224D1 (de) 2002-03-14
ES2172822T3 (es) 2002-10-01
EP0956009B1 (en) 2002-01-30
US6649811B2 (en) 2003-11-18
EP0956009A1 (en) 1999-11-17
NO992374D0 (no) 1999-05-18
IL129949A0 (en) 2000-02-29
NZ335726A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
NO992374D0 (no) Behandling av neurodegenerative tilstander med nimesulid
ATE290782T1 (de) Kombination von bisphosphonat und tetracyclin
WO2000037107A3 (en) Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
WO1999015167A3 (en) Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
EE200000741A (et) Kompositsioon osteoporoosi ja menopausi sündroomist tingitud muutuste ennetamiseks ja/või raviks
NO20001413D0 (no) Synergistisk sammensetning samt fremgangsmåter ved behandling av neoplasier og svulster samt for å restaurere eller forsterke hematopoese
NO953370D0 (no) Anvendelse av riluzol ved behandling av neuro-AIDS
IL140159A0 (en) Neuroprotective composition for the prevention and/or treatment of nervous and behavioral alterations due to anxiety states or depression
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
AU6232794A (en) The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
MXPA05006178A (es) Modificacion de la actividad de la ciclooxigenasa y de la lipooxigenasa con extractos de asteridae y opcionalmente acido boswelico.
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
FI961380L (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
DE69322750D1 (de) Dibekacin und Arbekacin Derivate wirksam gegen resistente Bakterien, und ihre Herstellung
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
ZA916036B (en) Antiallergic combination
FI944687L (fi) Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi
NO20012777D0 (no) Anvendelse av riluzol ved behandling av akustiske traumer
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE491457T1 (de) Kombinationstherapie gegen tumoren mit substituierten acryloyl-distamycin-derivaten, taxanen und/oder antimetaboliten
ITMI961070A0 (it) Prevenzione e trattamento delle infezioni virali topiche con perfluoropolietere o loro composizioni.
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
徐志宏 et al. NOTE ON TWO NEW SPECIES OF DISCODES FOERSTER (HYMENO-PTERA: ENCYRTIDAE)
ID21653A (id) Komposisi untuk pengobatan atau pencegahan pankreatitis yang mengandung turunan diarilalkana sebagai bahan aktif
DE69933212D1 (de) Benzocarbazol und indenoindole derivate als östrogene agentien